帕金森病（PD）的准确诊断和病情评估影响治疗策略。研究人员开展 “帕金森病运动症状和多巴胺能功能障碍模式的纵向评估” 研究，用 DaTSCAN 分析 196 例患者，发现其与疾病严重程度等相关，对评估疾病进展有重要意义。 帕金森病，这个名字大家或许并不陌生 ...

DUBLIN--(BUSINESS WIRE)--GE Healthcare today presented the results of a randomised controlled study analyzing the effect of DaTSCAN™ (Ioflupane I 123 Injection) SPECT imaging in a group of adult ...

本综述系统探讨帕金森病（PD）神经炎症机制与精准诊断策略，重点评述FDA批准的DATscan（SPECT）成像技术及新型生物传感器 ...

DaTscan is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult ...

Parkinson’s disease (PD), the second-most common neurodegenerative disease, is characterized by motor and nonmotor symptoms. PD is often misdiagnosed; inappropriate treatment due to misdiagnosis has ...

First patient dosed in Phase III clinical trial for PET radiopharmaceutical Next stage clinical study also proceeding for SPECT radiopharmaceutical Both imaging agents aim to assist in the evaluation ...

January 17, 2011 — GE Healthcare has announced Food and Drug Administration (FDA) approval of ioflupane iodine-123 injection (DaTscan), a contrast agent for use with single-photon emission computed ...

This supplement to The American Journal of Managed Care summarizes proceedings from a roundtable meeting that was conducted to discuss the diagnosis of Parkinson’s disease and distinguish clinical ...

The FDA has approved DaTscan (Ioflupane I 123 Injection, from GE Healthcare) for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters (DaT) ...

GE Healthcare today presented the results of a randomized study analyzing the effect of DaTSCAN TM (Ioflupane I 123 Injection) SPECT imaging in a group of adult patients with a diagnosis of possible ...

GE Healthcare announced that DaTscan (Ioflupane I 123 Injection) is available for the detection of dopamine transporters (DaT) in the brains of adult patients with suspected Parkinsonian syndromes.